NEUPOGEN MARKET SIZE AND SHARE ANALYSIS - GROWTH TRENDS AND FORECASTS (2025 - 2032)

Global Neupogen Market Size and Forecast – 2025 to 2032

The Global Neupogen Market is expected to decline from USD 89.2 Mn in 2025 to USD 30.5 Mn by 2032, with a negative CAGR of -14.2% over the forecast period. While factors like cancer prevalence, chemotherapy-induced neutropenia, biosimilars adoption, and prophylactic treatment demand are influencing the market, competition, pricing pressures, and alternative therapies are limiting its growth.

Key Takeaways of the Global Neupogen Market

• Single-use vials are expected to lead the global Neupogen market, holding a 54.4% share in 2025.
• With respect to dose strength, the 300 mcg/1 mL segment is projected to dominate the market, accounting for 42.35% of the global share in 2025.
• In terms of indication, the chemotherapy-induced neutropenia in non-myeloid malignancies segment is anticipated to represent the largest share of the market at 44.3% in 2025.
• North America is expected to lead the market, holding a share of 39.3% in 2025.
• Asia Pacific is anticipated to be the fastest-growing region, with a market share of 26.3% in 2025.

Market Overview

The Neupogen market is influenced by the development and adoption of biosimilars, which provide cost-effective alternatives to the original biologic drugs. However, despite this trend, the overall market growth remains stagnant. Personalized medicine and targeted therapies are gaining attention, but they are not yet creating substantial growth for Neupogen itself. Furthermore, while there is increased awareness about the benefits of prophylactic treatment to prevent infections in cancer patients undergoing chemotherapy, the market is facing significant challenges that limit its expansion. Factors, such as increasing competition, pricing pressures, and the availability of alternative treatments, are constraining market growth during the forecast period.

Current Events and Its Impact

Uncover macros and micros vetted on 75+ parameters: Get instant access to report

Segmental Insights

To learn more about this report, Download Free Sample

Neupogen Market Insights, By Indication - Chemotherapy-induced neutropenia in non-myeloid malignancies segment dominates due to the increasing prevalence of non-myeloid malignancies

In terms of indication, the chemotherapy-induced neutropenia in non-myeloid malignancies segment is estimated to contribute the highest share of the market with 44.3% in 2025, owing to several factors. One of the primary drivers is the increasing prevalence of non-myeloid malignancies, such as breast cancer, lung cancer, and colorectal cancer, globally. As the incidence of these cancers continues to rise, the demand for chemotherapy treatments is also increasing, subsequently leading to a higher occurrence of chemotherapy-induced neutropenia.

Moreover, advancements in chemotherapy regimens have led to the development of more potent and targeted therapies, which, while effective in treating cancer, can also result in a higher incidence of neutropenia. The use of high-dose chemotherapy and combination therapies has become more common, further contributing to the increased risk of neutropenia in non-myeloid malignancy patients.

For instance, in May 2022, according to data provided by the National Library of Medicine, chemotherapy-induced neutropenia (FN) presents a significant burden in the U.S., with high hospitalization rates and mortality risks, especially in pediatric and adult cancer patients. The average cost per hospitalization is USD 40,000 for adults and USD 65,000 for pediatric patients. Prophylactic use of granulocyte colony-stimulating factors (G-CSFs) has been proven to reduce febrile neutropenia incidence and improve chemotherapy dose delivery.

Neupogen Market Insights, By Dose Strength - 300mcg/1mL segment is dominant attributed to its convenience, ease of use, and proven efficacy

In terms of dose strength, the 300mcg/1mL segment is projected to contribute the highest share of the global Neupogen market with a share of 42.35 % in 2025. This can be attributed to several factors that drive its growth and dominance within the market. Firstly, the 300mcg/1mL dose strength is widely considered to be the most convenient and user-friendly option for both healthcare providers and patients. The single-dose vial format allows for easy administration and reduces the risk of dosing errors, as compared to other available dose strengths that may require more complex preparation or administration techniques. This convenience factor has led to increased adoption of the 300mcg/1mL dose strength in various healthcare settings, from hospitals to outpatient clinics.

Moreover, the 300mcg/1mL dose strength has been extensively studied and has demonstrated excellent efficacy in managing neutropenia across a wide range of indications. Clinical trials have shown that this dose strength is effective in reducing the duration and severity of neutropenia, as well as the risk of associated complications, such as febrile neutropenia and infections. The proven efficacy of the 300 mcg/1mL dose strength has further contributed to its widespread acceptance and use among healthcare professionals.

Neupogen Market Insights, By Packaging - Single-use vials segment is dominant due to their key advantages in safety, sterility, and cost-effectiveness

Single-use vials segment is anticipated to dominate the global Neupogen market with a share of 54.4% in 2025, due to their key advantages in safety, sterility, and cost-effectiveness. The use of single-dose containers minimizes the risk of contamination and dosing errors, ensuring a safer treatment environment for both healthcare providers and patients. This is especially crucial for injectable medications like Neupogen, where maintaining a sterile, uncontaminated drug environment is essential.

Additionally, single-use vials offer cost savings by eliminating the need for complex sterilization and reducing medication wastage. They simplify the administration process for healthcare providers, with fixed doses that reduce the risk of errors. These factors, coupled with patient reassurance regarding the sterility of the vials, contribute to the continued dominance of single-use vials in the Neupogen market.

Pricing Analysis of the Neupogen Market

• The price of Neupogen varies significantly across different countries. In 2024, the average price for a 300 mcg/0.5 mL vial in the U.S. was approximately USD 366.23, while it is much lower in countries like India at USD 31. Other countries, such as France and Ireland, have a significantly lower price at around USD 68.4 and USD 68.2, respectively. The pricing disparity reflects factors like healthcare infrastructure, local regulations, and government pricing policies.
• Countries like Mexico, Saudi Arabia, and Japan offer Neupogen at intermediate prices, ranging from USD 121.2 to USD 291.1. While developed countries like the U.S., Australia, and Canada have relatively higher prices, emerging markets such as India benefit from more affordable access to the drug. This global pricing variation emphasizes the impact of local economic conditions, healthcare systems, and insurance coverage on the cost of cancer treatments like Neupogen.

Regional Insights

To learn more about this report, Download Free Sample

North America Neupogen Market Analysis and Trends

In North America, the dominance in the global Neupogen market can be attributed to several factors. The region is expected to account for a market share of 39.3% in 2025. The region boasts a well-established healthcare infrastructure, advanced medical technologies, and a high adoption rate of innovative treatments. The presence of major pharmaceutical companies, such as Amgen Inc., further strengthens the market ecosystem. For example, In the U.S., patients seeking reimbursement for Neupogen can use Amgen SupportPlus, a service provided by Amgen Inc. To qualify, patients must enroll in the Amgen co-pay card program, obtain prior authorization, and pay upfront at the pharmacy.

The rollout of favorable government policies, including expedited drug approval processes and supportive reimbursement schemes, has also contributed to the region's dominance. Moreover, the increasing prevalence of cancer and the growing demand for effective supportive care treatments have driven the market growth in North America. For instance, according to American Cancer Society, Inc. in the U.S., 1 in 2 men and 1 in 3 women will be diagnosed with cancer in their lifetime.

Asia Pacific Neupogen Market Analysis and Trends

The Asia Pacific region is expected to exhibit the fastest growth in the global Neupogen market with a share of 26.3% in 2025. Rapid economic development, improving healthcare infrastructure, and increasing healthcare expenditure in countries like China, India, and Japan have created a conducive environment for market expansion. The region's large population base, coupled with the rising incidence of cancer and other chronic diseases, has fueled the demand for Neupogen and other supportive care therapies. Furthermore, the increasing awareness about the benefits of Neupogen in managing chemotherapy-induced neutropenia has contributed to its growing adoption.

In June 2022, a study on cancer trends in Asia, published by the National Library of Medicine, revealed that in 2020, cancer cases in Asia accounted for 49.3% of global cancer incidences, with lung, breast, and colorectal cancers being the most common. As per the same source cancer-related deaths made up 58.3% of global cancer deaths, with lung, liver, and stomach cancers being the leading causes. The study highlighted an increase in cancer rates, particularly among women and individuals under 40, especially in countries like Korea, Japan, and China. Despite the rising incidence, overall cancer mortality in the region has been decreasing.

Global Neupogen Market Outlook for Key Countries

U.S. Neupogen Market Trends

The U.S. neupogen market continues to hold a significant share in the North American region, primarily due to its advanced healthcare system, extensive research, and strong intellectual property protection. However, despite these advantages, the market is facing challenges as the demand for Neupogen declines due to increasing competition from biosimilars and alternative treatments. Companies like Amgen Inc., which pioneered Neupogen's development, continue to maintain a strong presence in the market, though the growing availability of more affordable alternatives is impacting market growth. The increasing incidence of cancer and the continued demand for supportive care treatments are present, but market dynamics are evolving with a shift toward alternative therapies.

China Neupogen Market Trends

China Neupogen market, once growing rapidly, is now facing a slowdown due to the rise of biosimilars and more cost-effective treatment options. While the country’s growing healthcare infrastructure and increased prevalence of cancer continue to influence demand, the presence of local pharmaceutical companies like Jiangsu Hengrui Medicine and Qilu Pharmaceutical, which offer affordable alternatives to imported Neupogen, is limiting the market share of branded Neupogen. The government’s efforts to improve healthcare access, including insurance coverage and cancer center establishment, still support the market, but the competition from biosimilars is gradually reducing the need for the original Neupogen.

Japan Neupogen Market Trends

Japan remains a significant market in the Asia Pacific region for Neupogen; however, the market is facing a decline due to the increasing adoption of biosimilars and generics. The well-established healthcare system, aging population, and high incidence of cancer continue to create demand for supportive care treatments. However, the Japanese government's push for the use of biosimilars and generic drugs has caused a shift in the market dynamics, leading to a decrease in the demand for branded Neupogen. Japan's role in pioneering Boron Neutron Capture Therapy (BNCT) for targeted cancer treatment highlights the country's shift toward innovative and more targeted therapies, which are also affecting Neupogen's market presence.

For example, according to Springer Nature Limited, Japan is pioneering Boron Neutron Capture Therapy (BNCT), a targeted cancer treatment approved in 2020 for advanced or recurrent head and neck tumors. BNCT uses precise radiation that minimizes damage to healthy tissue by targeting tumors with boron and neutrons. It is now being used for more difficult cases, with over 500 patients treated so far, and other countries are following Japan's lead in developing similar facilities.

India Neupogen Market Trends

India Neupogen market, while still significant due to the country's large population and rising healthcare awareness, is facing challenges as the market shifts towards more affordable biosimilars. The government's initiatives, such as the Ayushman Bharat program, have expanded access to medical treatments, but with the rise of local manufacturers like Dr. Reddy’s Laboratories and Intas Pharmaceuticals providing affordable Neupogen biosimilars, the demand for the original Neupogen is decreasing. While the market holds potential, the growth of biosimilars is expected to continue reducing the market share of branded Neupogen in India.

Market Players, Key Developments, and Competitive Intelligence

To learn more about this report, Download Free Sample

Key Developments

• In July 2020, according to a research article by Elsevier Inc., a study on Neupogen for preventing febrile neutropenia (FN) in early-stage breast cancer (EBC) patients found that a 5-day treatment is non-inferior to the 7/10-day regimen. The 5-day schedule resulted in a lower risk of hospitalizations and similar FN rates compared to the longer treatment. The findings suggest that 5-day filgrastim could be the standard care, offering cost savings without compromising effectiveness.

Market Report Scope

Neupogen Market Report Coverage

Neupogen Market Dynamics

To learn more about this report, Download Free Sample

Neupogen Market Driver - Increasing Cancer Prevalence requiring Chemotherapy

The global Neupogen market is experiencing steady growth, driven by the consistent prevalence of cancer worldwide. While the demand for supportive care treatments, such as Neupogen, remains stable, it continues to meet the ongoing need for managing chemotherapy-induced neutropenia. Neupogen, a recombinant human granulocyte colony-stimulating factor (G-CSF), is essential in addressing the decrease in white blood cell counts caused by chemotherapy, which leaves patients vulnerable to infections. As chemotherapy remains a standard treatment for cancer, the demand for Neupogen is steady, but not growing rapidly. The market is maintaining a stable trajectory due to the continuous use of Neupogen in supportive care, but it is not experiencing significant expansion.

For instance, in March 2021, the Clinton Health Access Initiative (CHAI) and the American Cancer Society (ACS), expanded their Cancer Access Partnership (CAP) to enhance access to cancer treatments, including biologics and hormonal therapies, in low- and middle-income countries across Africa and Asia Pacific. This collaboration is expected to generate up to 60% savings on purchased medications. The announcement supports the World Health Organization’s Global Breast Cancer Initiative, which aims to reduce global breast cancer mortality by 2.5% annually, preventing 2.5 million deaths between 2020 and 2040.

Neupogen Market Opportunity - Development of Combination Therapies

The development of combination therapies presents a promising opportunity for the global Neupogen market. Neupogen, being a granulocyte colony-stimulating factor (G-CSF), has been extensively used to stimulate the production of white blood cells in patients undergoing chemotherapy or those with neutropenia. However, there is a growing interest in exploring the potential of combining Neupogen with other therapeutic agents to enhance its efficacy and expand its applications. Combination therapies involving Neupogen and other drugs, such as chemotherapeutic agents or immunotherapies, could potentially improve treatment outcomes, reduce side effects, and target specific cancer types more effectively. Moreover, the development of combination therapies opens up new avenues for research and innovation in the field of oncology and hematology.

In September 2023, The USFDA has approved motixafortide (Aphexda) in combination with filgrastim (Neupogen) to help mobilize hematopoietic stem cells for collection and subsequent autologous stem cell transplant (ASCT) in patients with multiple myeloma. The approval was based on data from the GENESIS trial, which showed that 67.5% of patients receiving the combination treatment achieved the target stem cell collection compared to just 9.5% with placebo. The combination therapy offers more reliable stem cell mobilization with fewer apheresis sessions and doses of filgrastim.

Analyst Opinion (Expert Opinion)

• The global Neupogen market is currently experiencing a decline, driven by increased competition from biosimilars and alternative therapies. While Neupogen has been a key treatment for neutropenia associated with chemotherapy, the market dynamics are shifting as more affordable biosimilars enter the market, reducing the drug’s market share. Additionally, the high cost of treatment and the growing focus on personalized medicine are contributing factors to the decrease in product demand in the market. The regulatory landscape, while supportive of biosimilars, is evolving to adapt to these changes, but it remains a challenge for established biologics like Neupogen to maintain their dominance.
• Recent initiatives and collaborations have sought to address these challenges. For instance, various biosimilar manufacturers have gained approval in major markets, including the U.S. and Europe, which has led to increased price competition. These shifts are reshaping the market’s landscape, with a growing emphasis on affordable alternatives and greater patient access. Conferences such as the Annual Biosimilars Congress and the European Hematology Association (EHA) Congress have highlighted these trends, offering platforms for knowledge-sharing on biosimilars and market strategies. However, as these alternatives continue to rise in prominence, Neupogen’s market outlook remains under pressure, with reduced growth potential in the coming years.

Market Segmentation

•  Indication Insights (Revenue, USD Mn, 2020 - 2032)
  • Chemotherapy-induced neutropenia in non-myeloid malignancies
  • Neutropenia in acute myeloid leukemia (AmL) patients post-induction or consolidation chemotherapy
  • Neutropenia post-myeloablative chemotherapy followed by bone marrow transplantation (BMT)
  • Mobilization of autologous hematopoietic progenitor cells for leukapheresis
  • Chronic neutropenia (congenital, cyclic, idiopathic)
  • Hematopoietic Syndrome of Acute Radiation Syndrome (H-ARS)
•  Dose Strength Insights (Revenue, USD Mn, 2020 - 2032)
  • 300mcg/1mL
  • 480mcg/1.6mL
  • 300MGC/0.5mL
  • 480mcg/0.8mL
•  Packaging Insights (Revenue, USD Mn, 2020 - 2032)
  • Single-use vials
  • Prefilled syringes
•  Patient Age Group Insights (Revenue, USD Mn, 2020 - 2032)
  • Pediatric
  • Adult
  • Geriatric
•  Sales Channel Insights (Revenue, USD Mn, 2020 - 2032)
  • Online
  • Offline
•  End User Insights (Revenue, USD Mn, 2020 - 2032)
  • Hospitals
  • Oncology Clinics
  • Ambulatory Surgical Centers
  • Others (Academic & Research Institutions, etc.)
• Regional Insights (Revenue, USD Mn, 2020 - 2032)
  • North America
    • U.S.
    • Canada
  • Latin America
    • Brazil
    • Argentina
    • Mexico
    • Rest of Latin America
  • Europe
    • Germany
    • U.K.
    • Spain
    • France
    • Italy
    • Russia
    • Rest of Europe
  • Asia Pacific
    • China
    • India
    • Japan
    • Australia
    • South Korea
    • ASEAN
    • Rest of Asia Pacific
  • Middle East
    • GCC Countries
    • Israel
    • Rest of Middle East
  • Africa
    • South Africa
    • North Africa
    • Central Africa
• Key Players Insights
  • Amgen Inc.

Sources

Primary Research Interviews

• Oncologists and Hematologists specializing in neutropenia treatments
• Hospital Pharmacists involved in the administration of Neupogen
• Healthcare professionals in oncology departments
• Pharmaceutical industry experts focusing on biologic drugs
• Clinical trial coordinators and investigators for neutropenia treatments

Databases

• U.S. Food and Drug Administration (FDA)
• European Medicines Agency (EMA)
• World Health Organization (WHO)
• Centers for Disease Control and Prevention (CDC)
• National Institutes of Health (NIH)
• U.S. National Library of Medicine (PubMed)
• Health Canada
• Global Health Observatory (GHO) by WHO

Magazines

• Pharmaceutical Technology
• Pharmaceutical Journal
• Oncology Times
• Journal of Oncology Pharmacy Practice
• Biopharma Reporter
• European Journal of Clinical Pharmacology
• The Pharmaceutical Journal

Journals

• Journal of Clinical Oncology
• Lancet Oncology
• Blood
• The New England Journal of Medicine
• Journal of Hematology & Oncology
• Cancer Chemotherapy and Pharmacology

Newspapers

• The New York Times
• The Guardian
• The Wall Street Journal
• Financial Times
• Reuters Health

Associations

• American Society of Clinical Oncology (ASCO)
• European Society for Medical Oncology (ESMO)
• American Society of Hematology (ASH)
• Pharmaceutical Research and Manufacturers of America (PhRMA)
• International Society for Pharmacoeconomics and Outcomes Research (ISPOR)
• Biotechnology Innovation Organization (BIO)

  Public Domain Sources

• U.S. National Cancer Institute (NCI)
• ClinicalTrials.gov
• OpenFDA
• World Bank Health Data
• PubMed Central (PMC)

Proprietary Elements

• CMI Data Analytics Tool: Proprietary analytics tool to analyze real-time market trends, consumer behavior, and technology adoption in market
• Proprietary CMI Existing Repository of Information for the Last 8 Years